We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Neovascular age-related macular degeneration
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The Light Touch study looks at patients with neovascular age-related macular degeneration (nAMD) who have been receiving regular intravitreal injections and would be eligible to switch to a new agent, faricimab. The usual approach to switching would require an initial 4 injections over 4 months. This study looks at whether starting treatment with fewer drug injections (i.e., a "light touch") can still help patients see well, aiming to make treatment less demanding by reducing the number of doctor visits and injections needed.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Individuals who have not previously received anti-angiogenic treatment. 2. Prior administration of faricimab to the study eye. 3. Presence of fibrosis or atrophy in the central 1 mm of the ETDRS grid, active ocular inflammation, or infection in the study eye. 4. Tractional retinal detachment, preretinal fibrosis, or macular thickening secondary to an epiretinal membrane or vitreomacular traction affecting the macular architecture. 5. Any current or history of ocular disease other than nAMD that may confound assessment of the macula or affect central vision in the study eye. 6. Presence of uncontrolled glaucoma. 7. Any intraocular surgery within 3 months prior to randomization. 8. Females who are pregnant, breastfeeding, or intending to become pregnant during the study period. 9. Systolic blood pressure greater than 180 mmHg or diastolic pressure greater than 100 mmHg at rest. 10. History of stroke or myocardial infarction within the last 6 months. 11. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the investigational drug or might affect interpretation of the results, or renders the patient at high risk for treatment complications.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Moorfields Eye Hospital and funded by Roche.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS: 63966
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
